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ABSTRACT. We evaluated the association between TP53 gene 
polymorphisms and endometriosis in Brazilian women. Genomic 
DNA was extracted from swabs of buccal cells collected from hospital 
patients. TP53 gene polymorphisms were investigated at three 
codons: TP53*11 Glu/Gln or Lys (GAG->CAG or AAG), TP53*72 
Arg/Pro (CCG->CCC), and TP53*248 Arg/Thr (CGG->TCG) using 
the polymerase chain reaction-restriction fragment length polymorphism 
method. TP53*11 presented the following genotypic distribution: the 
control group was 98.28% homozygous wild-type (Glu) and 1.72% 
homozygous variant (Gln/Lys), and the heterozygous genotype was 
not identified. The genotypic distribution in the endometriosis group 
was 96% homozygous wild-type (Glu) and 4% heterozygous (Glu-Gln/
Lys); the homozygous variant genotype was not identified (P = 0.02). 
TP53*72 showed the following genotypic distribution: the control 
group was 29.75% homozygous wild-type (Arg), 47.11% heterozygous 
(Arg-Pro), and 23.14% homozygous variant (Pro). The genotypic 
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distribution in the endometriosis group was 16.15% homozygous wild-
type (Arg), 51.54% heterozygous (Arg-Pro), and 32.31% homozygous 
variant (Pro) (odds ratio = 2.26; 95% confidence interval = 1.19-4.03; 
P = 0.02). Only one patient had the homozygous TP53*248 genotype 
(Arg-Trp/Gln); all other patients were homozygous wild-type in both 
the control and endometriosis groups (P = 0.51; NS). We found that 
TP53*72 polymorphism may be associated with susceptibility to 
endometriosis; the presence of at least 1 polymorphic allele increased 
the chance of disease development by 2.26-fold. Hence, this genetic 
variant is a potential candidate marker for endometriosis.
Key words: Cell cycle; Endometriosis; Gene polymorphism; p53; 
TP53 
INTRODUCTION
Endometriosis is a benign gynecological disease defined by the presence of functional 
endometrial implants outside of the uterus, primarily in the pelvis, that may cause inflammato-
ry lesions (Ulukus et al., 2006; Falconer et al., 2007). Regardless of the polygenic inheritance 
established, the etiology of endometriosis remains unknown (Falconer et al., 2007; Hansen 
and Eyster, 2010). Various patterns of cell cycle alterations such as proliferation enhancement 
and diminished apoptosis have been described in the context of pathophysiology for both eu-
topic and ectopic endometria in affected women, suggesting that this tissue displays neoplastic 
behavior. In addition, reported genetic polymorphisms may be responsible for the neoplastic 
phenotype of the endometrium and ectopic implants (Falconer et al., 2007). 
p53 is one of the most important proteins controlling the cell cycle and apoptosis, act-
ing as a gatekeeper during cell division (Levine, 1997). Proper functioning of p53 is essential 
for preventing tumor development, as tumor protein p53 gene (TP53) mutations are associated 
with instability of cell cycle progression (Loging and Reisman, 1999). p53 induces up- or down-
regulation of several genes involved in cell cycle progression in response to oncogenic stress or 
various other stresses such as DNA repair, senescence, or apoptosis (Loging and Reisman, 1999; 
Vogelstein et al., 2000; Vousden and Lu, 2002). Genetic characterization of human cancer has 
shown that p53 is inactivated by different types of mutations in 50% of cases (Joerger and Fersht, 
2008). Thus, functional loss of the TP53 gene may be associated with tumor development and 
aberrant protein expression in cervical carcinoma (Zehbe et al., 1999), ovarian carcinoma (Ku-
pryjanczyk et al., 1994), bladder cancer (Esrig et al., 1994), prostate cancer (Steiner et al., 2000), 
and other types of cancers (Boley et al, 2000; Miyazaki et al., 2000; Nutt et al., 2000). 
The most common TP53 gene polymorphism is at codon 72, in which an arginine to 
proline substitution is associated with an increased risk of tumor development (Boldrini et al., 
2008; de Carvalho et al., 2008; Vieira et al., 2008; Akkiprik et al., 2009). In addition, TP53 
gene polymorphisms at codons 11 and 248 are related to lung tumor (Hussain et al., 2001), 
ovarian cancer (Manahan et al., 2001), and acute lymphoblastic leukemia (Zhou et al., 1998).
These previous studies suggest that TP53 gene polymorphisms are associated with 
cell cycle aberrations, including gynecological malignances. In addition, endometriosis le-
sions display cell cycle disturbances and neoplastic behavior. Thus, we evaluated the associa-
tion between TP53 gene polymorphisms and endometriosis in Brazilian women. 
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MATERIAL AND METHODS
Study population
This transversal study was performed between January 2007 and December 2009 and 
included a total of 130 women with surgically and histopathologically confirmed diagnosis of 
endometriosis and 124 post-menopausal women without endometriosis.
The control group presented normal gynecological and pelvic ultrasonographic evalu-
ations, and reported having no history of infertility or any gynecological condition, such as 
pelvic pain and/or dyspareunia, during their reproductive lives. These women were also free 
of endocrine-related diseases and/or cancer before and at the time of the study. The average 
age of the patients in the endometriosis and control groups were 34.9 ± 7.0 years and 58.5 ± 
7.8 years, respectively (P < 0.0001).
The study was approved by the Research Ethics Committee of the Universidade 
Federal de São Paulo under protocol number 0856/03; all participants agreed with and signed 
an informed consent form. 
Genotype assay
A brush used to collect buccal swabs (Cytobrush; Trumbull, CT, USA) from each 
patient was inserted in a tube containing 0.9% NaCl solution immediately after collection. 
The swabs were centrifuged at 2500 xg for 5 min, the supernatants were discarded, 
and genomic DNA was extracted from the pellets using the illustra™ blood genomicPrep 
Spin Kit (GE Healthcare; Piscataway, NJ, USA) according to manufacturer instructions. The 
polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) condi-
tions used to amplify the fragments containing the TP53 codons 11, 72, and 248 have been 
previously described (Nutt et al., 2000).
Briefly, amplifications were carried out in a 25-µL volume using a PCR standard 
master mix (Master Mix; Eppendorf; Hamburg, Germany). The cycling conditions varied in 
the annealing temperature and polymerization time used, between 55°C and 58°C and 30 
and 45 s for TP53*11/TP53*72 and TP53*248, respectively. General PCR conditions were: 
initial denaturation at 94°C for 5 min, 40 cycles of denaturation at 94°C for 30 s, anneal-
ing at 55°C or 58°C for 30 s, polymerization at 72°C for 30 s or 45 s, and final extension 
at 72°C for 7 min. The following primer sequences were used for amplification: TP53*11: 
CTTGGGTTGTGGTGAAACATTG (sense) and GTCAGTCCCATGAATTTTCGCT (anti-
sense); TP53*72: (sense) TCCCCCTTGCCGTCCCAA and CGTGCAAGTCACAGACTT 
(antisense); TP53*248: TAGGTTGGCTCTGACTGTACCA (sense) TGTGATGAGAGGTG
GATGGGTA (antisense). These primers amplified fragments of 379 base pairs (bp) at the 
TP53*11 codon, 279 bp at the TP53*72 codon, and 233 bp at the TP53*248 codon. Restriction 
enzyme digestion of the TP53*11 amplicon with TaqI (New England Biolabs; Ipswich, MA, 
USA) at 65°C for 30 min produced 2 fragments of 239 bp and 140 bp, indicating the presence 
of the wild-type allele (Glu), whereas digestion resulting in only 1 fragment of 379 bp indicat-
ed the presence of the variant allele (Gln/Lys). Restriction enzyme digestion of the TP53*72 
amplicon with BstUI (New England Biolabs) at 37°C for 4 h produced 1 fragment of 279 bp 
and indicated the presence of the wild-type allele (Arg); observation of 2 fragments of 160 
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bp and 119 bp indicated the presence of the variant allele (Pro). Digestion of the TP53*248 
amplicon with HpaII (New England Biolabs) at 37°C for 4 h produced 2 fragments of 167 bp 
and 69 bp, indicating the presence of the wild-type allele (Arg); observation of 1 fragment of 
233 bp indicated the presence of the variant allele (Trp/Gln). 
Statistical analysis
To analyze whether the data obtained regarding the presence of genotypes as homozy-
gous wild-type, homozygous mutant, or heterozygous mutant were in Hardy-Weinberg equi-
librium, a 2 x 2 contingency table was constructed, where the null hypothesis (h0) was given 
by the expected frequencies and the alternative hypothesis (h1) was the observed frequencies 
for these polymorphisms. The chi-squared test (χ2) was used to determine whether the sample 
was in Hardy-Weinberg equilibrium. A P value higher than 0.05 indicated Hardy-Weinberg 
equilibrium.
Analyses were performed using the SPSS software (v14.0; SPSS, Inc.; Chicago, IL, 
USA). The χ2 or Fisher exact test was used based on the variables assessed, such as frequen-
cies and proportions. The Student t-test or the Mann-Whitney U test was used for numerical 
variables. The statistical significance value was established at 5% (P < 0.05).
RESULTS 
TP53*11 polymorphism 
A total of 241 patients were included in the TP53*11 polymorphism group. The 
control group presented the following genotypic distribution: 98.28% homozygous wild-type 
(Glu) and 1.72% homozygous variant allele (Gln/Lys); the heterozygous genotype was not 
identified. The genotypic distribution in the endometriosis group was 96% homozygous wild-
type (Glu) and 4% heterozygous (Glu-Gln/Lys); the homozygous variant genotype was not 
identified (P = 0.02). Table 1 represents the panel of TP53 gene polymorphism frequencies. 
Evaluation of the TP53*11 polymorphism based on the allelic distribution and considering 
only the wild-type (Glu) and variant alleles (Gln/Lys) showed no statistical differences 
between groups (P = 0.54).
TP53*72 polymorphism
A total of 251 patients were included in the TP53*72 polymorphism group. The con-
trol group presented the following genotypic distribution: 29.75% homozygous wild-type 
(Arg), 47.11% heterozygous (Arg-Pro), and 23.14% homozygous for the allele variant (Pro). 
The genotypic distribution in the endometriosis group was 16.15% homozygous wild-type 
(Arg), 51.54% heterozygous (Arg-Pro), and 32.31% homozygous for the variant allele (Pro) 
(P = 0.02). Values for the presence of the allele encoding Pro in the minimal/mild endome-
triosis group were 23.68% and 48.91% in the moderate and severe groups, respectively (P 
< 0.0003). The comparative allelic frequencies of the TP53*72 polymorphism between the 
minimal/mild and moderate/severe endometriosis groups are represented in Table 2. 
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TP53*248 polymorphism 
Only 1 patient in the TP53*248 polymorphism group, the endometriosis group, pre-
sented a heterozygous genotype (Arg-Trp/Gln); all the other participants had the homozygous 
wild-type genotype in both the control and endometriosis groups (P = 0.51).
DISCUSSION
The search for a genetic marker of endometriosis is important for increasing the pos-
sibility of early diagnosis. Currently, there are no markers that can be used to predict this 
disease; hence, early diagnoses are rare. In addition, clarification of various aspects of the 
pathogenesis of this disease, also guided by potential markers, may improve future diagnosis 
and treatment prospects. 
Cell cycle aberrations have being described in topic and ectopic endometria in women 
with endometriosis in recent years (Velarde et al., 2009; Schor et al., 2009; Aghajanova et al, 
2010). Because this may be due to genetic alterations such as polymorphisms, some studies 
were performed to evaluate polymorphisms in genes that encode proteins involved in cell cycle 
control; however, the results of these studies have been inconclusive. Fernandéz et al. (2005) 
studied the FAS and FASL genes; Hsieh and Lin (2006) evaluated P21waf1 gene polymorphisms. 
These studies reported no differences in polymorphism frequencies between women with and 
without endometriosis (Fernández et al., 2005; Hsieh and Lin, 2006; Velarde et al., 2009; 
Schor et al, 2009; Aghajanova et al., 2010). However, other studies showed significant differ-
ences in the prevalence of gene polymorphisms that encode proteins involved in regulating 
the cell cycle (Fernández et al., 2005; Hsieh and Lin, 2006; Velarde et al., 2009; Schor et al., 
2009; Aghajanova et al., 2010). Camargo-Kosugi et al. (2009) reported a 2.0-fold increase in 
the likelihood of endometriosis in women who carried at least 1 variant allele in the P27 gene.
A study of TP53 gene mutation and its association with endometriosis, first performed 
by Vercellini et al. (1994) involving only 10 women, showed no differences in polymorphism 
frequencies between women with or without the disease. Similarly, no differences were report-
ed in other studies performed in Japanese (Omori et al., 2004) and Italian women (Lattuada et 
al., 2004; Vietri et al., 2007; Ammendola et al., 2008). 
A study conducted in Taiwan was the only study describing differences in the TP53 
gene polymorphism at codon 72 in patients with and without endometriosis (Hsieh and Lin, 
2006). This study reported genotype prevalence rates of 9.5% for wild-type (Arg-Arg), 66.2% 
for heterozygous (Arg-Pro), and 24.3% for homozygous (Pro) genotypes in the experimental 
group (endometriosis), as well as 30.7% for wild-type (Arg-Arg), 50% for the heterozygous 
mutant (Arg-Pro), and 19.3% for the homozygous mutant in the control group. These results 
Table 2. Allele frequencies of TP53 gene polymorphism at codon 72 between endometriosis groups.
TP53 polymorphism  Population studied         Allele frequencies (N, %)   P value
   N Arg Pro 
Codon 72  Minimal/mild endometriosis   76 58 (76.31) 18 (23.69)  <0.0003*** 
  Moderate/severe endometriosis 184 94 (51.09) 90 (48.91) 
Chi-square test; odds ratio = 3.08; 95%CI = 1.68-5.63. ***P < 0.001.
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are similar to those of the present study in which the following prevalence rates were observed 
in the endometriosis group: 16.15% for wild-type (Arg-Arg), 51.54% for the heterozygous al-
leles (Arg-Pro), and 32.31% for the homozygous (Pro) alleles, as well as 29.75% for wild-type 
(Arg-Arg), 47.11% for the heterozygous variant (Arg-Pro), and 23.14% for the homozygous 
variant in the control group. 
It has been well established that different ethnic backgrounds are associated with dif-
ferent genetic polymorphisms. This may explain the differences between the results obtained 
in this current study and those of Lin et al. (1994) and Hsieh and Lin (2006), among others 
(Omori et al., 2004; Lattuada et al., 2004; Vietri et al., 2007; Ammendola et al., 2008). A study 
involving a larger population sample size may confirm these data. 
It is important to emphasize that this study included women at the mean age (± stan-
dard deviation, SD) of 58.5 ± 7.8 years in the control group. These women were within an age 
range indicative of past reproductive life; they reported the absence of any symptoms that may 
be related to endometriosis, such as pelvic pain and/or dyspareunia, no infertility history and 
no long-term estrogen treatments. Therefore, despite difference in the mean age between the 
groups compared in this study, the control group participants presented a reduced chance of 
developing endometriosis. The A/G polymorphism in the follicle-stimulating hormone recep-
tor gene was studied in Taiwanese women using a control group composed of postmenopausal 
women (Wang et al., 2011). In other studies that included younger women in the control 
groups, it was unknown whether these women, regardless of reporting no history of pelvic 
disease (Riiskjaer et al., 2011) or neonates (Ammendola et al., 2008), would develop endome-
triosis in the future. 
Brazilian women included in the present study were from a multiracial population. 
Because many diseases are associated with different ethnicities, the inclusion of women from 
a multiracial population resulted in a more comprehensive study. Furthermore, the evaluation 
of Hardy-Weinberg equilibrium validated the sample population in this study, indicating that 
no allele was underrepresented.
TP53 is a major tumor suppressor gene capable of responding to several stress signals 
(Vogelstein et al., 2000). Activation of this gene may stop cell cycle progression and induce 
senescence and apoptosis, which may prevent malignant cell proliferation, inhibition of tumor 
growth, repair of genomic damage, and elimination of potential oncogenic cells (Nakayama 
et al., 2001). The wild-type p53 protein functions as a transcription factor that activates tumor 
suppressor genes including P21, MDM2, GADD45, and Bax. These proteins are necessary 
for the regulation and progression of the cell cycle or apoptosis as responses to DNA damage 
(Loging and Reisman, 1999). In addition, functional loss of the p53 protein may be associated 
with the development of tumors in approximately 50% of all human solid tumors including 
several gynecological tumors (Kupryjanczyk et al., 1994; Zehbe et al., 1999).
The results reported by Hsieh and Lin et al. (2006) regarding the Glu11 polymorphism 
corroborate the results obtained in this study: the presence of the wild-type allele Glu11 was ob-
served in 96% of women in the endometriosis group and 98.28% in the control group. Despite 
the statistically significant difference observed in this study, the relative rarity of this mutation 
indicates that it may not play a relevant role in endometriosis pathogenesis (Hsieh and Lin, 
2006; Aghajanova et al., 2010). The TP53 gene polymorphism at codon 248 (TP53*248) was 
reported in several studies of solid tumors (Lin et al., 1994; Hussain et al., 2001; Wang et al., 
2001). Nevertheless, in the present study, no statistically significant difference was detected.
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However, a significant difference between groups was observed in the TP53*72 gene 
polymorphism. When comparing the Arg-Arg genotype (homozygous wild-type) with geno-
types showing at least 1 variant allele (Arg-Pro and Pro-Pro), the mutation was significantly 
more frequent in the endometriosis group than in the control group. These results suggest that 
the presence of only 1 mutated allele increases the chances of developing endometriosis dis-
ease by more than 2-fold [odds ratio (OR) = 2.26; 95% confidence interval (CI) = 1.19-4.03; 
P = 0.02]. Furthermore, the association was also evident in the comparison of allele distribu-
tions of Arg and Pro in patients with moderate-to-severe endometriosis (OR = 3.08; 95% CI= 
1.68-5.63; P = 0.0003).
In conclusion, the TP53*72 polymorphism was more frequently observed in the en-
dometriosis group than in the control group. The TP53*72 polymorphism may be associated 
with susceptibility to endometriosis; therefore, the presence of at least 1 polymorphic allele 
could double a patient’s chance of developing the disease. Hence, this genetic variant may be 
a marker of endometriosis.
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